The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Status of c‐erb B‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay
Open accessAbstract
c‐erb‐2 amplification and overexpression are currently attracting a great deal of attention because a new adjuvant therapy using an antibody against the c‐erb B‐2 gene product, trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), has proved effective in treating breast cancer with amplification and/or overexpression of c‐erb B‐2. Aberrations of c‐erb B‐2 have also been detected in ovarian, endometrial and gastric carcinomas at varied frequencies. Amplification of the c‐erb B‐2 locus (17q12‐q21.32), overexpression of c‐erb B‐2 protein (p185) and serum levels of soluble c‐erb B‐2 protein fragments (p105) were examined in gastric cancer patients using fluorescence in situ hybridization (FISH), immunohistochemistry and enzyme‐linked immunosorbent assay (ELISA), respectively. Overexpression of c‐erb B‐2 protein was found in 29 (8.2%) of the 352 gastric carcinomas analyzed. In FISH analysis, all tumors with 3+ immunostaining and 1 of 5 tumors with 2+ staining showed high‐level amplification of c‐erb B‐2. Pre‐operative serum p105 was quantified in serum specimens from 129 patients with gastric cancer and 28 patients with benign diseases. There were no significant differences in the serum p105 levels among 11 patients with c‐erbB‐2‐overexpressing carcinomas, 118 patients with c‐erbB‐2 non‐overexpressing carcinomas and 28 controls, although a single case of gastric carcinoma overexpressing c‐erbB‐2 with extensive liver metastasis had a higher level than the cut‐off value. The mechanisms of overexpression of p185 and high‐level amplification of c‐erb B‐2 in gastric adenocarcinomas seem similar to those well‐established in breast cancers. Patients having gastric adenocarcinoma with c‐erb B‐2 amplification are potential candidates for a new adjuvant therapy using humanized monoclonal antibody. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Cited by
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Tanner, M., Hollmén, M., Junttila, T. T., Kapanen, A. I., Tommola, S., Soini, Y., Helin, H., Salo, J., Joensuu, H., Sihvo, E., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi064 · Cited by 665
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem, E., Bang, Y.-J., Feng-yi, F., Xu, J. M., Lee, K.-W., Jiao, S.-C., Chong, J. L., López-Sanchez, R. I., Price, T., Gladkov, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0402-y · Cited by 608
Metadata
- Authors
- Takehana, T., Kunitomo, K., Kono, K., Kitahara, F., Iizuka, H., Matsumoto, Y., Fujino, M. A., & Ooi, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-02-19
- Volume
- 98
- Issue
- 6
- Pages
- 833-837
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2097988373
- Cited by
- 195
- References
- 1
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.